Search

Your search keyword '"Benning, Louise"' showing total 16 results
Start Over Author "Benning, Louise" Publication Type Magazines
16 results on '"Benning, Louise"'

2. Immune Response to COVID-19 mRNA Vaccination in Previous Nonresponder Kidney Transplant Recipients After Short-term Withdrawal of Mycophenolic Acid 1 and 3 Months After an Additional Vaccine Dose

Author

Kühn, Tessa, Speer, Claudius, Morath, Christian, Bartenschlager, Marie, Kim, Heeyoung, Beimler, Jörg, Buylaert, Mirabel, Nusshag, Christian, Kälble, Florian, Reineke, Marvin, Töllner, Maximilian, Klein, Katrin, Blank, Antje, Parthé, Sylvia, Schnitzler, Paul, Zeier, Martin, Süsal, Caner, Bartenschlager, Ralf, Tran, Thuong Hien, Schaier, Matthias, and Benning, Louise

Published
2023
Full Text
View/download PDF

3. Induction of Long-Lasting Regulatory B Lymphocytes by Modified Immune Cells in Kidney Transplant Recipients

Author

Morath, Christian, Schaier, Matthias, Ibrahim, Eman, Wang, Lei, Kleist, Christian, Opelz, Gerhard, Süsal, Caner, Ponath, Gerald, Aly, Mostafa, Alvarez, Cristiam M., Kälble, Florian, Speer, Claudius, Benning, Louise, Nusshag, Christian, Pego da Silva, Luiza, Sommerer, Claudia, Hückelhoven-Krauss, Angela, Czock, David, Mehrabi, Arianeb, Schwab, Constantin, Waldherr, Rüdiger, Schnitzler, Paul, Merle, Uta, Tran, Thuong Hien, Scherer, Sabine, Böhmig, Georg A., Müller-Tidow, Carsten, Reiser, Jochen, Zeier, Martin, Schmitt, Michael, Terness, Peter, Schmitt, Anita, and Daniel, Volker

Abstract

In previous work, the authors demonstrated that kidney transplant recipients developed donor-specific unresponsiveness when they were given a pretransplant infusion of modified donor-derived PBMCs. In this study, they provide evidence that the immunosuppressive properties of these cells persist and the donor-specific unresponsiveness is long-lasting. In the four patients who received the highest dose of the modified immune cells, administration of these cells was associated with a striking increase in IL-10–producing regulatory B lymphocytes and evidence of the consensus gene expression signature of operational tolerance. In vitro, donor-specific unresponsiveness was abolished after B lymphocyte depletion, suggesting a direct pathophysiologic role for regulatory B lymphocytes. These findings support the notion that modified donor-derived PBMCs may be useful in kidney transplantation, but this approach requires further validation and rigorous controlled randomized studies.

Published
2023
Full Text
View/download PDF

4. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients

Author

Benning, Louise, Morath, Christian, Bartenschlager, Marie, Kim, Heeyoung, Reineke, Marvin, Beimler, Jörg, Buylaert, Mirabel, Nusshag, Christian, Kälble, Florian, Reichel, Paula, Töllner, Maximilian, Schaier, Matthias, Klein, Katrin, Benes, Vladimir, Rausch, Tobias, Rieger, Susanne, Stich, Maximilian, Tönshoff, Burkhard, Weidner, Niklas, Schnitzler, Paul, Zeier, Martin, Süsal, Caner, Hien Tran, Thuong, Bartenschlager, Ralf, and Speer, Claudius

Abstract

Seroconversion after COVID-19 vaccination is impaired in kidney transplant recipients. Emerging variants of concern such as the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants pose an increasing threat to these patients. In this observational cohort study, we measured anti-S1 IgG, surrogate neutralizing, and anti-receptor-binding domain antibodies three weeks after a third mRNA vaccine dose in 49 kidney transplant recipients and compared results to 25 age-matched healthy controls. In addition, vaccine-induced neutralization of SARS-CoV-2 wild-type, the B.1.617.2 (delta), and the B.1.1.529 (omicron) variants was assessed using a live-virus assay. After a third vaccine dose, anti-S1 IgG, surrogate neutralizing, and anti-receptor-binding domain antibodies were significantly lower in kidney transplant recipients compared to healthy controls. Only 29/49 (59%) sera of kidney transplant recipients contained neutralizing antibodies against the SARS-CoV-2 wild-type or the B.1.617.2 (delta) variant and neutralization titers were significantly reduced compared to healthy controls (p< 0.001). Vaccine-induced cross-neutralization of the B.1.1.529 (omicron) variants was detectable in 15/35 (43%) kidney transplant recipients with seropositivity for anti-S1 IgG, surrogate neutralizing, and/or anti-RBD antibodies. Neutralization of the B.1.1.529 (omicron) variants was significantly reduced compared to neutralization of SARS-CoV-2 wild-type or the B.1.617.2 (delta) variant for both, kidney transplant recipients and healthy controls (p< .001 for all).

Published
2022
Full Text
View/download PDF

5. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS‐CoV‐2 vaccine dose in kidney transplant recipients

Author

Benning, Louise, Morath, Christian, Bartenschlager, Marie, Kim, Heeyoung, Reineke, Marvin, Beimler, Jörg, Buylaert, Mirabel, Nusshag, Christian, Kälble, Florian, Reichel, Paula, Töllner, Maximilian, Schaier, Matthias, Klein, Katrin, Benes, Vladimir, Rausch, Tobias, Rieger, Susanne, Stich, Maximilian, Tönshoff, Burkhard, Weidner, Niklas, Schnitzler, Paul, Zeier, Martin, Süsal, Caner, Hien Tran, Thuong, Bartenschlager, Ralf, and Speer, Claudius

Abstract

Seroconversion after COVID‐19 vaccination is impaired in kidney transplant recipients. Emerging variants of concern such as the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants pose an increasing threat to these patients. In this observational cohort study, we measured anti‐S1 IgG, surrogate neutralizing, and anti‐receptor‐binding domain antibodies three weeks after a third mRNA vaccine dose in 49 kidney transplant recipients and compared results to 25 age‐matched healthy controls. In addition, vaccine‐induced neutralization of SARS‐CoV‐2 wild‐type, the B.1.617.2 (delta), and the B.1.1.529 (omicron) variants was assessed using a live‐virus assay. After a third vaccine dose, anti‐S1 IgG, surrogate neutralizing, and anti‐receptor‐binding domain antibodies were significantly lower in kidney transplant recipients compared to healthy controls. Only 29/49 (59%) sera of kidney transplant recipients contained neutralizing antibodies against the SARS‐CoV‐2 wild‐type or the B.1.617.2 (delta) variant and neutralization titers were significantly reduced compared to healthy controls (p< 0.001). Vaccine‐induced cross‐neutralization of the B.1.1.529 (omicron) variants was detectable in 15/35 (43%) kidney transplant recipients with seropositivity for anti‐S1 IgG, surrogate neutralizing, and/or anti‐RBD antibodies. Neutralization of the B.1.1.529 (omicron) variants was significantly reduced compared to neutralization of SARS‐CoV‐2 wild‐type or the B.1.617.2 (delta) variant for both, kidney transplant recipients and healthy controls (p< .001 for all). A third mRNA vaccine dose increases immunogenicity in most kidney transplant recipients but, in comparison to healthy controls, kidney recipients have significantly reduced cross‐neutralizing antibody activity against the immune‐escaping B.1.1.529 (omicron) variant.

Published
2022
Full Text
View/download PDF

7. Neutralization of SARS-CoV-2 Variants of Concern in Kidney Transplant Recipients after Standard COVID-19 Vaccination

Author

Benning, Louise, Morath, Christian, Bartenschlager, Marie, Nusshag, Christian, Kälble, Florian, Buylaert, Mirabel, Schaier, Matthias, Beimler, Jörg, Klein, Katrin, Grenz, Julia, Reichel, Paula, Hidmark, Asa, Ponath, Gerald, Töllner, Maximilian, Reineke, Marvin, Rieger, Susanne, Tönshoff, Burkhard, Schnitzler, Paul, Zeier, Martin, Süsal, Caner, Bartenschlager, Ralf, and Speer, Claudius

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results